ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1212

Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)

Peter Taylor1, Bryan Downie2, Emon Elboudwarej2, Sam Kim2, Angie Hertz2, Amer Mirza2, Jeff Siegel3, Rachael Hawtin2 and Jinfeng Liu2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, 3Gilead Sciences, Inc., Foster City, CA

Meeting: ACR Convergence 2020

Keywords: Gene Expression, Outcome measures, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we described molecular response to FIL in large-scale RNA sequencing studies of gene expression in other RA populations1-3.We conducted a similar study in methotrexate (MTX)-naïve RA patients (pts) (FINCH3; ClinicalTrials.gov NCT02886728) to identify gene transcripts and biological pathways associated with RA and altered in response to FIL.

Methods: MTX-naïve RA pts received stable dose of MTX+placebo (PBO+MTX), FIL 200mg alone (FIL 200mg), FIL 100mg+MTX, or FIL 200mg+MTX. Whole blood samples were collected using PAXgene tubes at baseline (BL), weeks 4, 12, and 24. RNA was extracted and sequenced on Illumina HiSeq 2500 platform following globin RNA depletion. Correlations between BL gene expression and disease measurements were performed using Spearman’s rank partial correlation to account for covariates. Differentially expressed genes (DEGs) were identified using voom-limma. Biological pathway analyses were performed on Molecular Signature Database v6.1 using single sample gene set enrichment analysis with focus on immune signaling pathways from Kyoto Encyclopedia of Genes and Genomes (KEGG). A false-discovery rate of 5% was applied.

Results: Differential gene expression analyses comparing BL samples with after-treatment samples showed rapid onset of transcriptional changes in FIL pts. Fewer DEGs were observed in PBO+MTX patients with peak number at week 24, an observation consistent with MTX clinical response kinetics.4 Up to 3x as many significant DEGs were observed in FIL 200mg+MTX compared to FIL 100mg+MTX arm, a finding consistent with superior clinical efficacy of FIL 200mg. As with other FIL clinical trial RNA-seq studies and consistent with the selective MoA of FIL, JAK-STAT pathway-induced genes SOCS2 and CISH were significantly downregulated across FIL arms and timepoints, but not PBO+MTX. RA disease activity-associated genes2-3 FAM20A and METTL7B were significantly reduced at all timepoints in FIL pts, but only at week 24 in PBO+MTX. While no significant changes in KEGG immune signaling pathways were observed in PBO+MTX arm, a dose-dependent effect on pathway modulation was observed in FIL arms, including reductions in JAK-STAT, toll-like receptor, chemokine, and RIG-I like receptor signaling.

Conclusion: More rapid and sustained changes of transcriptional activity in whole blood transcriptional profile of RA pts after FIL treatment were found compared to PBO+MTX. Dose dependent changes were observed in FIL-treated pts, most notably in KEGG JAK-STAT signaling pathway. These observations confirm an inhibition of JAK-STAT signaling by FIL and are consistent with observed clinical efficacy of FIL in these pts. 

  1. Taylor PC, et al. (EULAR 2018). http://dx.doi.org/10.1136/annrheumdis-2018-eular.3759
  2. Taylor PC, et al. (ACR 2018). https://doi.org/10.1093/rheumatology/kez105.001
  3. Taylor PC, et al. (EULAR 2019). http://dx.doi.org/10.1136/annrheumdis-2019-eular.2509
  4. Taylor PC, et al. J Clin Med. 2019;8(4): pii: E515. doi: 10.3390/jcm8040515

Disclosure: P. Taylor, Eli Lilly, 2, 5, 8, Celgene, 2, 5, 8, AbbVie, 2, 5, 8, Biogen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celltrion, 2, 5, 8, Fresenius, 2, 5, 8, GlaxoSmithKline, 2, 5, 8, Janssen, 2, 5, 8, Nordic Pharma, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8, Pfizer, 2, 5, 8, Gilead, 2, 5, 8, Galapagos, 2, 5, 8; B. Downie, Gilead Sciences, Inc., 3, Gilead Sciences, Inc., 1; E. Elboudwarej, Gilead Sciences, Inc., 3, Gilead Sciences, Inc., 1; S. Kim, Gilead Sciences, Inc., 1, 3; A. Hertz, Gilead Sciences, Inc., 1, 3; A. Mirza, Gilead Sciences, Inc., 3, Gilead Sciences, Inc., 1; J. Siegel, Gilead Sciences, Inc., 1, 3, Gilead Sciences, Inc., 3, Roche, Inc., 1; R. Hawtin, Gilead Sciences, Inc., 3, Gilead Sciences, Inc., 1; J. Liu, Gilead Sciences, Inc., 3, Gilead Sciences, Inc., 1, Roche, 1.

To cite this abstract in AMA style:

Taylor P, Downie B, Elboudwarej E, Kim S, Hertz A, Mirza A, Siegel J, Hawtin R, Liu J. Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/whole-blood-transcriptional-changes-following-selective-inhibition-of-janus-kinase-1-jak1-by-filgotinib-in-mtx-naive-adults-with-moderately-to-severely-active-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-blood-transcriptional-changes-following-selective-inhibition-of-janus-kinase-1-jak1-by-filgotinib-in-mtx-naive-adults-with-moderately-to-severely-active-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology